Company: ACBM
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001640334-25-001347
Chunk: 6

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-08-05
Form: 10-Q
Item: Item 1
Chunk 6
---
 common stock was not eligible for proprietary broker-dealer quotes.  There are no market makers for the Company’s common stock.  At present, the Company’s common stock is not eligible for proprietary broker-dealer quotations and all quotes reflect unsolicited customer orders.  Unsolicited only stocks have a higher risk of wider spreads, increased volatility, and price dislocations. Investors may have difficulty selling this stock. An initial review by a broker-dealer under SEC Rule15c2-11 is required for brokers to publish competing quotes and provide continuous market making.  Accordingly, there are no published quotes for the Company’s common stock and the Company cannot assure you that a broker-dealer will take the necessary steps to make a market in its common stock.  These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Although the Company proposes to fund operations through sales of its products and equity financing arrangements, it does not presently have any orders for products, its common stock is reported on the Expert Market as a result of which there are no market makers in the common stock and it is delinquent in its filings with the Securities and Exchange Commission, as a result of which the Company may not be able to raise funds for capital expenditures, working capital and other cash requirements and will have to rely on advances from a minority stockholder and an officer. If the Company cannot generate revenue from its products, it may not be able to continue in its business.

NOTE 4 - RELATED PARTY TRANSACTIONS AND BALANCES During the six months ended June 30, 2025 and 2024, a minority stockholder who is not a 5% stockholder advance $0 and $1,000 and paid expenses of $116,065 and $19,392 on behalf of the Company, respectively. During the three months ended June 30, 2025 and 2024, such minority stockholder advanced $0 and $1,000 and paid expenses of $93,759 and $6,104 on behalf of the Company, respectively. At June 30, 2025 and December 31, 2024, the Company owed $240,553 and $124,488 to the minority stockholder referred to in the preceding paragraph for non-interest-bearing advances made to or expenses paid on behalf of the Company, and these amounts are